ArticleJournal of gastroenterology2026
Immediate prediction of post-ERCP pancreatitis: a novel approach using serum trypsin.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs trypsin activation occurs early in the pathogenesis of pancreatitis, evaluating serum trypsin (TRY) may allow immediate prediction of post-ERCP pancreatitis (PEP). This study aims to evaluate the diagnostic performance of TRY measurement for predicting PEP.
methodsThis multicenter prospective observational study was conducted at 12 tertiary centers in Japan. Serum TRY, amylase (AMY), pancreatic-type AMY (P-AMY), and lipase (LIP) were measured before ERCP, immediately post-procedure (0 h), and 2 h post-procedure. Predictive performances of pancreatic enzymes for PEP were evaluated using receiver operating characteristic (ROC) analysis, Youden's index, and DeLong's test.
resultsPEP was identified in 48 of the 463 patients analyzed (10.3%). The optimal 0-h TRY cut-off was 2043 ng/mL, yielding an area under the ROC curve (AUC) of 0.83 (68.7% sensitivity, 84.6% specificity), significantly higher than those of 0-h AMY (AUC 0.74, p = 0.002), 0-h P-AMY (0.78, p = 0.007), or 0-h LIP (0.80, p = 0.048). At 2-h, TRY showed an AUC of 0.89, superior to 2-h AMY (0.84) and comparable to 2-h P-AMY (0.89) and 2-h LIP (0.90). When cutoffs were set as 2 × , 2.5 × and 3 × of the upper limit of normal, TRY consistently showed higher sensitivity than AMY or P-AMY. TRY showed the earliest and steepest post-procedural increase among all enzymes in patients with PEP.
conclusionsTRY measured immediately after ERCP provides significantly better early prediction of PEP than conventional enzymes. Rapid measurement of TRY may enable immediate risk stratification, potentially improving clinical outcomes.
Indexed as
Identifiers
42412125What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.